Journal of Clinical Endocrinology & Metabolism, Vol 75, 1459-1463, Copyright © 1992 by Endocrine Society

ARTICLES

Octreotide stimulates insulin-like growth factor-binding protein-1: a potential pituitary-independent mechanism for drug action

S Ezzat, SG Ren, GD Braunstein and S Melmed
Department of Medicine, Cedars-Sinai Medical Center, University of California School of Medicine, Los Angeles 90048.

As the long-acting somatostatin analog octreotide attenuates polypeptide hormone hypersecretion, it has recently been used to effectively treat acromegaly and gastrointestinal carcinoid tumors. Most growth-promoting actions of GH are mediated by insulin-like growth factor-I (IGF-I), which circulates complexed with multiple binding proteins (IGFBPs). IGFBP-1, a nonglycosylated peptide, competes with the IGF-I receptor for ligand binding and also regulates IGF action. To examine GH-independent mechanisms for octreotide regulation of the GH axis, circulating levels of IGFBP-1 were measured hourly after sc octreotide or saline administration in normal and GH-deficient adults. As IGFBP-1 is inhibited by insulin and GH, the dynamic pattern of alterations in GH and insulin levels was also assessed. After octreotide (100 micrograms) administration to 10 normal subjects, mean IGFBP-1 concentrations were stimulated from 23 +/- 4 to 72 +/- 18 micrograms/L (P < 0.007 vs. saline) after 2 h. Maximal induction of IGFBP-1 levels occurred after 3 h (325 +/- 115 micrograms/L; P < 0.02 vs. saline) and remained elevated (P < 0.005) for 6 h. IGFBP-1 was induced by octreotide in all subjects and was confirmed by Western ligand blotting. Insulin and GH levels preceding the rise in IGFBP-1 were unaltered by octreotide. Octreotide stimulated IGFBP-1 5-fold during a sustained fast in 4 normal subjects, despite equally suppressed insulin levels in both saline- and octreotide-treated groups. In 4 GH-deficient adults, IGFBP-1 levels were stimulated by octreotide from 16 +/- 3 to 146 +/- 36 and 154 +/- 28 micrograms/L after 3 and 4 h, respectively. In conclusion, the somatostatin analog octreotide induces IGFBP-1 independently of GH and insulin. As IGFBP-1 regulates the action of IGF-I, octreotide stimulation of IGFBPs may represent an additional pharmacological mechanism for attenuating the GH-IGF-I axis.

This article has been cited by other articles:

				A. Giustina, S. Bonadonna, G. Bugari, A. Colao, R. Cozzi, S. Cannavo, L. de Marinis, E. degli Uberti, F. Bogazzi, G. Mazziotti, et al. High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial Eur. J. Endocrinol., August 1, 2009; 161(2): 331 - 338. [Abstract] [Full Text] [PDF]

				R. von Essen, R. Ostermaier, E. Grube, W. Maurer, U. Tebbe, R. Erbel, M. Roth, W. Oel, J. Brom, G. Weidinger, et al. Effects of Octreotide Treatment on Restenosis After Coronary Angioplasty : Results of the VERAS Study Circulation, September 2, 1997; 96(5): 1482 - 1487. [Abstract] [Full Text]

				A. M. Mirza, S. Ezzat, and A. A. Axelrad Insulin-Like Growth Factor Binding Protein-1 Is Elevated in Patients With Polycythemia Vera and Stimulates Erythroid Burst Formation In Vitro Blood, March 15, 1997; 89(6): 1862 - 1869. [Abstract] [Full Text] [PDF]

				A. K. Flogstad, J. Halse, S. Bakke, I. Lancranjan, P. Marbach, Ch. Bruns, and J. Jervell Sandostatin LAR in Acromegalic Patients: Long Term Treatment J. Clin. Endocrinol. Metab., January 1, 1997; 82(1): 23 - 28. [Abstract] [Full Text] [PDF]

				E. Carmina, F. Z. Stanczyk, R. S. Morris, P. D. K. Lee, G. Savjani, and R. A. Lobo Altered Regulation of Insulin-Like Growth Factor Binding Protein-I in Patients With Polycystic Ovary Syndrome Reproductive Sciences, November 1, 1995; 2(6): 743 - 747. [Abstract] [PDF]

				J. P. Holden, T. L. Butzow, G. A. Laughlin, M. Ho, A. J. Morales, and S. C. Yen Regulation of Insulin-Like Growth Factor Binding Protein-I During the 24-Hour Metabolic Clock and in Response to Hypoinsulinemia Induced by Fasting and Sandostatin in Normal Women Reproductive Sciences, January 1, 1995; 2(1): 38 - 44. [Abstract] [PDF]